LRIF1: A Potential Drug Target and Biomarker for Prostate, Breast and Neurodegenerative Diseases

Target Name: LRIF1

NCBI ID: G55791

LRIF1

LRIF1: A Potential Drug Target and Biomarker for Prostate, Breast and Neurodegenerative Diseases

Ligand-Dependent Nuclear Receptor Interacting Factor 1 (LRIF1) is a protein that plays a crucial role in cell signaling pathways. It is a key regulator of nuclear receptor interactions, which are critical for the development and progression of various diseases. Therefore, LRIF1 has been identified as a potential drug target and a biomarker for several diseases.

The nuclear receptor is a protein that plays a vital role in cell signaling pathways. It is a complex structure that consists of a transmembrane domain, an intracellular domain, and an extracellular domain. The transmembrane domain is responsible for the regulation of the receptor's activity, while the intracellular domain interacts with other proteins inside the cell. The extracellular domain is involved in the interaction with ligands, which are the molecules that activate the receptor.

LRIF1 is a non-coding RNA molecule that is expressed in various tissues and cells. It is a key regulator of nuclear receptor interactions and has been identified as a potential drug target and biomarker for several diseases. LRIF1 is composed of two subunits, which are spliced together to form a double-stranded RNA molecule.

The first subunit of LRIF1 is composed of 194 amino acid residues and is named LRIF1-long. It contains a unique N-terminal region that consists of a 26 amino acid residue-long conserved domain called the N-terminal transmembrane domain. This domain is involved in the regulation of LRIF1's activity and is the site of several important interactions.

The second subunit of LRIF1 is composed of 285 amino acid residues and is named LRIF1-short. It contains a unique C-terminal region that consists of a 36 amino acid residue-long conserved domain called the C-terminal transmembrane domain. This domain is involved in the regulation of LRIF1's activity and is the site of several important interactions.

LRIF1 plays a crucial role in the regulation of nuclear receptor interactions. It is a key regulator of the androgen receptor (AR), which is involved in the development and progression of prostate cancer. LRIF1 has been shown to interact with the AR and to regulate its activity.

LRIF1 has also been shown to play a role in the regulation of the estrogen receptor (ER), which is involved in the development and progression of breast cancer. LRIF1 has been shown to interact with the ER and to regulate its activity.

LRIF1 has also been shown to play a role in the regulation of the nuclear receptor NHR2, which is involved in the development and progression of neurodegenerative diseases. LRIF1 has been shown to interact with the NHR2 and to regulate its activity.

LRIF1 has also been shown to play a role in the regulation of the TGF-β receptor, which is involved in the development and progression of many diseases, including cancer. LRIF1 has been shown to interact with the TGF-β receptor and to regulate its activity.

In conclusion, LRIF1 is a protein that plays a crucial role in cell signaling pathways. It is a key regulator of nuclear receptor interactions and has been identified as a potential drug target and biomarker for several diseases. Further research is needed to fully understand the role of LRIF1 in cell signaling pathways and to develop effective treatments for the diseases it is involved in.

Protein Name: Ligand Dependent Nuclear Receptor Interacting Factor 1

Functions: Together with SMCHD1, involved in chromosome X inactivation in females by promoting the compaction of heterochromatin (PubMed:23542155). Also able to repress the ligand-induced transcriptional activity of retinoic acid receptor alpha (RARA), possibly through direct recruitment of histone deacetylases (PubMed:17455211). Also required for silencing of the DUX4 locus in somatic cells (PubMed:32467133)

The "LRIF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRIF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets